Citizens raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $167 from $141 and keeps an Outperform rating on the shares. Preliminary Phase 2 data for setmelanotide in Prader-Willi Syndrome show impressive early efficacy on body weight as well as hyperphagia, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals
- Promising Phase 2 Results for Rhythm Pharmaceuticals’ Setmelanotide in Prader-Willi Syndrome Boost Buy Rating
- Rhythm Pharmaceuticals price target raised to $150 from $129 at Morgan Stanley
- Rhythm Pharmaceuticals rises 15.6%
- Positive Phase 2 Trial Results Boost Rhythm Pharmaceuticals’ Outlook and Price Target